Prevalence of Claudin 18.2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma: A Systematic Review and Meta-Analysis
- 3 September 2026
- journal article
- review article
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1) , 209
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Claudin-18.2 expression is frequent in remnant gastric carcinoma and associated with microsatellite instability and Epstein–Barr viral infection phenotypesPathology, 2026
- Intratumoral heterogeneity and chemotherapy-induced alteration of CLDN18.2 expression in resectable gastric cancerInternational Journal of Clinical Oncology, 2026
- Histological and biomarker landscape of Claudin18.2-positive gastric and gastroesophageal junction cancers: a study of 937 casesVirchows Archiv, 2025
- CLDN18.2 expression in gastroesophageal adenocarcinoma: prevalence, heterogeneity, and prognostic implications in Spanish patientsVirchows Archiv, 2025
- Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancerESMO Open, 2024
- Expression of claudin 18.2 in poorly cohesive carcinoma and its association with clinicopathologic parameters in East Asian patientsPathology - Research and Practice, 2024
- Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinomaGastric Cancer, 2024
- Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal disseminationGastric Cancer, 2024
- Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancerESMO Open, 2023
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010